Uniqure NV

This proposal asks shareholders to formally adopt uniQure’s 2025 Dutch statutory annual accounts, which are prepared under EU-adopted IFRS for consolidated statements and under Book 2 of the Dutch Civil Code for company-only statements. Management seeks shareholder adoption because Dutch law and the company’s Articles require the general meeting to approve statutory accounts. The filing notes these statutory accounts differ from the U.S. GAAP consolidated financial statements in the Form 10-K and contain additional disclosures required under Dutch rules. Adoption is procedural but important: it completes formal statutory compliance and signals shareholder acceptance of the company’s reported results and legal disclosures for 2025. The Board recommends a simple majority vote in favor and has unanimously recommended shareholders adopt the accounts. The proposal presents no substantive governance change or transaction risk but is a legal formality that can have consequences for later liability claims if shareholders later allege undisclosed matters. For analysts, adoption confirms that the formal Dutch-year reporting package is available and reconciles with the U.S. filings; any material divergence between statements would be a red flag. Given the Board’s unanimous support and routine nature, this is a straightforward, low-risk vote that supports corporate housekeeping and statutory compliance.

This Dutch-law proposal asks shareholders to grant discharge (release from liability) to Board members for actions taken in fiscal 2025 to the extent those actions are reflected in or disclosed by the statutory annual accounts and statutory board report. Such discharges are customary for Dutch companies and, if granted, limit the ability of shareholders to later bring personal liability claims against directors for conduct already disclosed. The vote is effectively a look-back on 2025 governance and financial disclosure: approval indicates shareholder acceptance of the reported conduct and results, while withholding discharge can signal shareholder concerns. The company frames the matter as routine and the Board unanimously recommends approval, but auditors’ and lawyers’ reviews of the statutory accounts and the board report bear on the practical risk of future claims. For investors, a withheld discharge can attract scrutiny and potentially trigger investigations; a granted discharge is standard and supports management continuity. Given the company’s public reporting and audit, this proposal is ordinarily non-controversial and the Board’s unanimous recommendation suggests no unreported matters are expected to arise from 2025.

This management proposal seeks shareholder authorization under Dutch law to designate the Board as the competent body to issue ordinary shares and grant subscription rights for an 18-month period for up to 12,400,000 Ordinary Shares (≈19.7% of issued capital as of the proxy). Management frames the request as a recurring, market-standard delegation intended to provide timely flexibility to raise equity capital, consummate strategic transactions, or issue equity under compensation plans without convening costly and time-consuming extraordinary meetings. The company highlights its 2025 issuance (≈11.8M shares plus 0.5M pre-funded warrants raising $404.2M) to show precedent and the business need for such authority during market windows. The Board acknowledges dilution risk to existing shareholders but argues the authorization enables prompt execution of financing and strategic opportunities that could materially benefit the pipeline advancement and corporate strategy. The proposal includes customary safeguards: a defined share cap, time limit (18 months), and the statutory vote thresholds under Dutch law. Governance considerations include the Board’s discretion over pricing and timing, and the company’s proposal to also seek an authorization to limit pre-emptive rights (linked Proposal No. 7), which increases flexibility but can accelerate dilution absent shareholder participation. Institutional investors will weigh the company’s cash runway needs and pipeline milestones (e.g., AMT-130 regulatory progress) against potential dilution; the company’s recent capital-raising and stated uses of proceeds provide context supporting the request. Overall, this is a routine but consequential authorization that materially affects share supply; the Board’s unanimous recommendation and prior shareholder approvals indicate management expects support but investors should monitor post-authorization issuance plans and any use of the powers for large strategic transactions.

This proposal asks shareholders to authorize the Board, for 18 months and limited to the same aggregate cap described in Proposal 6, to exclude or limit statutory pre-emptive subscription rights on share issuances. Under Dutch law shareholders normally have a pro rata right to subscribe for new cash issues; delegating the power to exclude pre-emptive rights is customary for Dutch companies seeking the flexibility to price and place financings quickly or to use shares in strategic transactions. Management argues that without this power the company would face delay and cost associated with convening extraordinary meetings each time pre-emptive rights need to be disapplied; the company links this authorization directly to the issuance cap sought in Proposal 6. The proposal carries a higher adoption threshold in cases where less than 50% of issued capital is represented at the meeting (two-thirds of votes cast), which is a customary Dutch protective rule. Investor concerns include the possibility of accelerated dilution without the opportunity for existing shareholders to participate pro rata; therefore institutional holders typically expect clear disclosure and limits (time cap, share cap) and a stated intended use of proceeds. The Board frames the measure as consistent with prior practice and market norms for U.S.-listed, Dutch-incorporated companies; shareholders will evaluate it in the context of the company’s funding needs, pipeline milestones, and recent capital activity. From a governance perspective, linking the exclusion power to a defined issuance limit and a short time window (18 months) moderates the potential for open-ended dilution. Given the Board’s unanimous recommendation and prior shareholder precedents, this is likely to pass, but monitoring of subsequent issuances is warranted to ensure investor protections are respected.

This management proposal requests shareholder authorization for the Board to repurchase up to 10% of the Company’s issued share capital over an 18-month period at prices between nominal value and 110% of market price, by open-market or other permitted methods. The Board frames the proposal as a standard capital management tool: repurchases can be used to address perceived undervaluation, provide shares for compensation plans, or support M&A activity. Reauthorizing the program is routine for Dutch companies and echoes prior annual authorizations; the Board emphasizes that this authorization supersedes the previous authorization from 2025. From a governance perspective, repurchase programs can be shareholder-friendly when they reflect appropriate capital allocation, but they can also be used opportunistically to offset dilution from equity issuance or to support the stock price without improving fundamentals — investors will evaluate the company’s cash runway and capital needs versus buyback scale. The company’s recent equity raises (≈$404M net in 2025) and a $175M senior secured term loan facility demonstrate active balance-sheet management, making buyback authority reasonable provided financial priorities are respected. The simple-majority vote and Board unanimity on recommendation suggest management expects shareholder approval; institutional investors will monitor actual repurchase activity and disclosure of plans, sizes, and timing to ensure alignment with long-term shareholder value creation. Overall, this proposal is routine but materially affects capital structure; prudent execution and transparent reporting after approval are key to preserving investor trust.

This non-binding advisory 'say-on-pay' proposal asks shareholders to approve the overall 2025 compensation of uniQure’s named executive officers as disclosed in the proxy materials. Management frames the program as aligned with strategic imperatives, designed to attract and retain talent, and linked to financial, strategic and operational goals set by the Compensation Committee. The advisory vote does not affect specific contractual pay elements but is intended to provide feedback to the Compensation Committee and Board; the Board states it will consider the outcome in future compensation decisions. Key contextual items for evaluation include the mix of pay (base, short-term cash incentives tied to corporate and individual goals, and long-term equity awards in options/RSUs), the company’s 2025 operational achievements (clinical program milestones and significant capital raises), and governance features such as clawback policy, equity plan governance and the peer benchmarking process. Investors will weigh whether pay outcomes are commensurate with performance given both positive pipeline progress (e.g., AMT-130 data milestones and fundraising) and any regulatory or developmental setbacks. The Board’s unanimous recommendation to approve suggests management expects support, but institutional investors routinely evaluate detailed CD&A disclosures, target/realized pay, and pay-for-performance alignment before voting. Because the vote is advisory, a negative result would typically trigger further engagement and potential compensation program changes rather than immediate contractual effects.

This advisory proposal asks shareholders to indicate their preferred frequency for future 'say-on-pay' votes — once every year, two years, or three years — with the Board explicitly recommending an annual ('ONE YEAR') frequency. The vote is non-binding but strongly informative: boards typically use the shareholder-preferred frequency as governance guidance when scheduling advisory votes. Management’s stated rationale for recommending annual votes includes investor preference and the Company’s history of annual advisory votes since 2019; annual votes provide more frequent shareholder feedback on compensation design and payouts, helping the Compensation Committee calibrate programs between meetings. Institutional investors will weigh administrative costs and the value of annual feedback versus potential short-termism from more frequent votes; some investors prefer triennial votes to focus on long-term strategy. The Board’s recommendation signals a willingness to accept regular shareholder scrutiny and may reflect active governance engagement and ongoing compensation program evolution. Because the vote is advisory, the Board retains discretion and will consider the outcome in setting future practice; however, a strong shareholder consensus for an alternative cadence could prompt the Board to change its schedule. For analysts evaluating governance quality, the Board’s push for annual votes is a pro-transparency stance but should be evaluated alongside compensation structure to ensure it promotes long-term value rather than reactionary changes.

This proposal requests shareholder approval to amend and restate the company’s 2014 equity incentive plan to add 350,000 shares to the plan reserve (increasing total plan capacity to 11,040,279 shares), permit incentive stock options consistent with U.S. tax rules, conform to Nasdaq listing requirements, and extend the plan’s term by one year. Management argues the incremental reserve is necessary to maintain competitive equity grant capacity given hiring, promotions and typical grant practices; the filing cites metrics such as historical burn rate, overhang, and remaining capacity through end-2026 to justify the increase. The proposal also seeks a Dutch-law designation authorizing the Board, for 18 months, to issue shares and exclude/limit pre-emptive rights specifically for awards under the amended plan — a formality to enable execution without convening extraordinary meetings. Investor considerations include the modest size of the incremental increase (350,000 shares, ≈0.5% of fully diluted shares as-of March 31, 2026), historical grant practices (mix of options and RSUs), and governance protections (minimum vesting rules, anti-repricing without shareholder approval, and clawback policy). The Compensation Committee used peer benchmarking and engaged an independent consultant; investors will assess whether award sizes and grant practices remain aligned with performance outcomes and long-term shareholder value. While dilutive, the proposed increase appears calibrated to avoid abrupt shocks to overhang; approval is likely if investors believe the program supports talent retention needed to advance clinical programs. Post-approval, investors should monitor grant pacing, disclosure on usage of the new reserve, and linkages between equity expense and operational milestones to judge ongoing program discipline.

This management proposal asks shareholders to amend the Articles to reflect the Dutch "large company" (structuur) regime that will apply by operation of law on August 10, 2026. The structuuregime changes governance mechanics: executive directors will be appointed/suspended/dismissed by the body of non-executive directors; non-executive director appointments will be based on nominations by non-executive directors with enhanced recommendation rights for the Works Council for a subset of seats; certain committee composition and nomination/ dismissal voting thresholds change (e.g., general meeting’s rejection/dismissal thresholds tied to one-third of issued capital); and additional technical clarifications are proposed (gender-neutral language, dividend record dates, property-law clarifications for shares, indemnity exceptions, temporary replacements). Management presents the amendment largely as aligning the Articles with legal requirements that will take effect by statute and as an opportunity to clean up technical provisions. For investors, the notable governance implication is the shift in some appointment and dismissal rights toward non-executive directors and the Works Council’s enhanced recommendation role for certain seats, which changes the locus of control relative to U.S.-style board appointment processes and may affect director independence dynamics. However, the company emphasizes safeguards including minimum board composition and committee representation rules. The Board recommends approval; this is primarily a compliance-driven change rather than a discretionary governance policy shift, but investors should read the precise text in Appendix B/C to assess any nuanced changes to shareholder powers and director appointment/dismissal mechanics. Overall, adoption appears necessary to align the charter with statutory changes, but shareholders should note the effect on nomination and dismissal pathways and the formal role the Works Council will have under Dutch structure rules.

This proposal would increase the company’s authorized share capital from EUR 4,000,000 (80,000,000 shares at EUR 0.05) to EUR 5,000,000 (100,000,000 shares), creating 20,000,000 additional shares of authorized capacity. Management frames the amendment as a practical step to provide flexibility for financing, acquisitions, and equity incentive needs without implying immediate issuance; under Dutch law this requires a charter amendment. The company notes the existing outstanding and available shares (≈71.6M outstanding, ≈8.34M available on a fully diluted basis as of March 31, 2026) and argues the current authorization may be insufficient for future needs. For investors the governance implication is that while authorized share increases do not dilute shareholders by themselves, larger authorized caps facilitate future dilution if the Board exercises issuance authorities; thus investors commonly look for corresponding limits, board designations, and disclosure of planned use. The Board links this proposal to ordinary capital-management flexibility rather than a specific issuance plan; the resolution also authorizes notaries to execute the required notarial deed. Given the time-bound authorizations requested in other proposals (e.g., Proposal 6) and recent capital raises in 2025, this amendment is coherent with management’s capital strategy, but shareholders should monitor any consequent issuances and ensure transparent reporting on use of the incremental capacity. The Board’s unanimous recommendation signals management expects shareholder approval.

This proposal would add a forum-selection clause to the Articles specifying U.S. federal district courts as the exclusive forum for claims asserted under the U.S. Securities Act (unless the Company consents to a different forum). Management argues this promotes efficiency, reduces forum shopping and prevents parallel state and federal cases, facilitating consolidated handling of securities litigations. From an investor perspective, federal forum clauses can reduce litigation cost and duplicative filings and are common among U.S.-listed foreign issuers, but they may constrain shareholders’ choice of forum and can raise access cost concerns for some litigants. The filing acknowledges enforceability risk (courts may find such clauses inapplicable) and warns shareholders of potential procedural consequences. Investors assessing this measure typically balance the Company's interest in litigation uniformity against shareholder rights to select litigation venues; many institutional investors view federal forums as reasonable for federal securities claims but may seek carve-outs for other claim types. The Board’s unanimous recommendation indicates it expects shareholder approval; governance-focused investors will monitor litigation outcomes and any challenges to enforceability to understand long-term implications for shareholder litigation rights.